Marker Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.52 Insider Own3.90% Shs Outstand83.11M Perf Week-28.93%
Market Cap38.01M Forward P/E- EPS next Y-0.46 Insider Trans0.00% Shs Float66.66M Perf Month19.94%
Income-43.00M PEG- EPS next Q-0.12 Inst Own28.50% Short Float1.29% Perf Quarter21.25%
Sales2.20M P/S17.28 EPS this Y10.30% Inst Trans0.03% Short Ratio0.49 Perf Half Y-28.68%
Book/sh0.43 P/B0.93 EPS next Y6.80% ROA-60.80% Target Price2.88 Perf Year-79.09%
Cash/sh0.30 P/C1.33 EPS next 5Y- ROE-85.80% 52W Range0.25 - 2.05 Perf YTD-57.97%
Dividend- P/FCF- EPS past 5Y-9.00% ROI-95.20% 52W High-80.52% Beta1.29
Dividend %- Quick Ratio3.80 Sales past 5Y- Gross Margin- 52W Low59.76% ATR0.06
Employees56 Current Ratio3.80 Sales Q/Q- Oper. Margin- RSI (14)52.02 Volatility12.54% 11.69%
OptionableYes Debt/Eq0.00 EPS Q/Q23.30% Profit Margin- Rel Volume0.22 Prev Close0.39
ShortableYes LT Debt/Eq0.00 EarningsAug 11 AMC Payout- Avg Volume1.76M Price0.40
Recom2.00 SMA205.18% SMA5017.95% SMA200-35.31% Volume384,887 Change1.47%
Mar-25-21Initiated Piper Sandler Overweight $6
Mar-19-21Initiated Cantor Fitzgerald Overweight $6
May-12-20Downgrade Piper Sandler Overweight → Neutral $5 → $2.50
May-30-19Initiated ROTH Capital Buy
Mar-01-19Initiated Janney Buy
Dec-03-18Upgrade Piper Jaffray Neutral → Overweight
Aug-11-22 04:22PM  
Aug-04-22 04:37PM  
Jun-15-22 07:06AM  
May-13-22 07:00AM  
May-04-22 10:30AM  
Apr-26-22 07:00AM  
Mar-17-22 05:45PM  
Mar-07-22 04:05PM  
Feb-17-22 01:08PM  
Feb-16-22 04:30PM  
Feb-08-22 04:05PM  
Jan-20-22 06:38AM  
Jan-19-22 04:49PM  
Jan-06-22 08:53AM  
Dec-31-21 09:40AM  
Dec-09-21 07:00AM  
Nov-18-21 04:05PM  
Nov-10-21 04:05PM  
Oct-08-21 09:24AM  
Sep-07-21 04:05PM  
Aug-20-21 12:00PM  
Aug-19-21 04:05PM  
Aug-10-21 04:01PM  
Aug-09-21 06:57AM  
Jul-28-21 04:05PM  
Jul-06-21 07:00AM  
Jun-29-21 09:01AM  
Jun-16-21 04:05PM  
May-20-21 04:06AM  
May-12-21 04:05PM  
Apr-29-21 04:05PM  
Apr-27-21 07:41PM  
Apr-08-21 03:23PM  
Apr-07-21 08:32AM  
Mar-16-21 04:57PM  
Mar-15-21 07:00AM  
Mar-12-21 08:00AM  
Mar-11-21 04:10PM  
Mar-09-21 04:12PM  
Mar-03-21 07:00AM  
Mar-01-21 05:03AM  
Jan-13-21 07:00AM  
Jan-05-21 07:00AM  
Nov-30-20 02:30AM  
Nov-09-20 04:01PM  
Nov-02-20 07:00AM  
Sep-17-20 07:00AM  
Aug-10-20 04:00PM  
Jun-30-20 07:00AM  
Jun-23-20 07:00AM  
Jun-10-20 02:14PM  
Jun-02-20 06:34AM  
May-29-20 08:00AM  
May-13-20 05:01PM  
May-11-20 04:05PM  
May-04-20 04:05PM  
Apr-30-20 12:32PM  
Apr-29-20 04:05PM  
Apr-11-20 01:59PM  
Apr-10-20 06:24PM  
Mar-12-20 04:01PM  
Mar-02-20 07:00AM  
Feb-18-20 07:00AM  
Feb-11-20 07:00AM  
Jan-06-20 10:01AM  
Dec-17-19 05:45PM  
Nov-25-19 07:00AM  
Nov-12-19 04:01PM  
Nov-11-19 07:00AM  
Nov-07-19 02:51PM  
Oct-08-19 10:32AM  
Aug-15-19 04:01PM  
Aug-08-19 04:01PM  
Aug-06-19 04:05PM  
Jul-20-19 11:00AM  
Jul-17-19 07:00AM  
Jun-28-19 06:01PM  
Jun-20-19 07:00AM  
Jun-13-19 06:08AM  
May-21-19 07:00AM  
May-10-19 01:47PM  
May-09-19 05:55PM  
May-07-19 04:10PM  
Apr-17-19 12:22PM  
Mar-29-19 10:22AM  
Mar-28-19 04:05PM  
Mar-18-19 07:00AM  
Feb-25-19 07:00AM  
Feb-21-19 06:00PM  
Feb-20-19 07:00AM  
Feb-15-19 04:30PM  
Feb-07-19 07:00AM  
Feb-06-19 07:00AM  
Feb-04-19 10:26AM  
Jan-17-19 07:00AM  
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.